Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20235716 | 0.89 | NMT2 (0.40) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL14932630 | 0.86 | NMT2 (0.44) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL20235799 | 0.80 | FURIN (0.47) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL20235576 | 0.79 | SIRT6 (0.39) | FURINSIRT6SIRT1PRSS1CACNA1B | |
| SCHEMBL16231521 | 0.79 | NMT1 (0.42) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL12812737 | 0.78 | SIRT6 (0.39) | NMT2NMT1SIRT6SIRT1SLC6A5 | |
| SCHEMBL13811926 | 0.78 | NMT1 (0.55) | NMT2NMT1FURINPRSS1TLR2 | |
| SCHEMBL20235814 | 0.78 | SIRT6 (0.37) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL20235809 | 0.77 | FURIN (0.47) | NMT2NMT1FURINSIRT6SIRT1 | |
| SCHEMBL31652408 | 0.76 | SLC6A5 (0.46) | NMT2NMT1FURINPRSS1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626438-B2 | Fluorescent substrates for determining lysine modifying enzyme activity | THE BROAD INSTITUTE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180155760-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | BROAD INST INC (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155760-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | KDM1A, MAN2B1, KDM3A | NMT2 1157/4885NMT1 376/4885FURIN 354/4885 |
| US-10626438-B2 | Fluorescent substrates for determining lysine modifying enzyme activity | KDM1A, MAN2B1, KDM3A | NMT2 1157/4885NMT1 376/4885FURIN 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.